{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:20:07Z","timestamp":1792516807888,"version":"4.5.0"},"reference-count":78,"publisher":"Harborside Press, LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:p>Infectious complications are among the leading causes of mortality in chronic lymphocytic leukemia (CLL). Over the past decade, several advances have been made in treating CLL through inhibition of Bruton tyrosine kinase and the antiapoptotic protein BCL-2. As mortality from CLL progression is expected to decline in the next several years, mortality from severe infections is anticipated to increase. Therefore, understanding the nature of immune defects in CLL and developing strategies to augment the impaired immune system are needed to keep pace with advancements in treatment. This review article summarizes the available data on immune dysfunctions, their clinical consequences, therapeutic implications, and current strategies to enhance immune function in patients with CLL.<\/jats:p>","DOI":"10.6004\/jnccn.2024.7090","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T09:13:27Z","timestamp":1741770807000},"source":"Crossref","is-referenced-by-count":10,"title":["Immune Dysfunction and Consequences in Chronic Lymphocytic Leukemia"],"prefix":"10.6004","volume":"23","author":[{"given":"Mayur","family":"Narkhede","sequence":"first","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB, Birmingham, AL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaitra S.","family":"Ujjani","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"CA Cancer J Clin","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel RL","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023;73:17\u201348."},{"key":"B2","series-title":"Ann Oncol","first-page":"23","article-title":"Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst B","year":"2021","unstructured":"Eichhorst B, Robak T, Montserrat E,  Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2021;32:23\u201333."},{"key":"B3","series-title":"Blood","first-page":"2745","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek M","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D,  iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 2018;131:2745\u20132760."},{"key":"B4","series-title":"Br J Haematol","first-page":"394","article-title":"Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study","volume":"178","author":"Strati P","year":"2017","unstructured":"Strati P, Parikh SA, Chaffee KG,  Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study. Br J Haematol 2017;178:394\u2013402."},{"key":"B5","series-title":"Leuk Res","first-page":"107496","article-title":"Evaluating population-level outcomes in chronic lymphocytic leukemia in the era of novel therapies using the SEER registry","volume":"140","author":"Muthiah C","year":"2024","unstructured":"Muthiah C, Narra R, Atallah E,  Evaluating population-level outcomes in chronic lymphocytic leukemia in the era of novel therapies using the SEER registry. Leuk Res 2024;140:107496."},{"key":"B6","series-title":"Blood","first-page":"573","article-title":"Perturbation of the normal immune system in patients with CLL","volume":"126","author":"Forconi F","year":"2015","unstructured":"Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood 2015;126:573\u2013581."},{"key":"B7","series-title":"Clin Cancer Res","first-page":"1959","article-title":"Improved innate immune function in patients with chronic lymphocytic leukemia treated with targeted therapy in clinical trials","volume":"30","author":"Svanberg Teglgaard R","year":"2024","unstructured":"Svanberg Teglgaard R, Marquart HV, Hartling HJ,  Improved innate immune function in patients with chronic lymphocytic leukemia treated with targeted therapy in clinical trials. Clin Cancer Res 2024;30:1959\u20131971."},{"key":"B8","series-title":"Blood","first-page":"2252","article-title":"Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib","volume":"139","author":"Purroy N","year":"2022","unstructured":"Purroy N, Tong YE, Lemvigh CK,  Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib. Blood 2022;139:2252\u20132256."},{"key":"B9","series-title":"Trends Immunol","first-page":"592","article-title":"B cell receptor signaling in chronic lymphocytic leukemia","volume":"34","author":"Burger JA","year":"2013","unstructured":"Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol 2013;34:592\u2013601."},{"key":"B10","series-title":"J Immunol","first-page":"2200","article-title":"Modulation of NF-\u03baB activity and apoptosis in chronic lymphocytic leukemia B cells","volume":"164","author":"Furman RR","year":"2000","unstructured":"Furman RR, Asgary Z, Mascarenhas JO,  Modulation of NF-\u03baB activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 2000;164:2200\u20132206."},{"key":"B11","series-title":"Hematol Oncol Clin North Am","first-page":"173","article-title":"Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications","volume":"27","author":"Herishanu Y","year":"2013","unstructured":"Herishanu Y, Katz BZ, Lipsky A, Wiestner A. Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications. Hematol Oncol Clin North Am 2013;27:173\u2013206."},{"key":"B12","series-title":"Oncogene","first-page":"4673","article-title":"The tumor microenvironment shapes hallmarks of mature B-cell malignancies","volume":"34","author":"Shain K","year":"2015","unstructured":"Shain K, Dalton W, Tao J. The tumor microenvironment shapes hallmarks of mature B-cell malignancies. Oncogene 2015;34:4673\u20134682."},{"key":"B13","series-title":"Front Oncol","first-page":"1422.","article-title":"Importance of crosstalk between chronic lymphocytic leukemia cells and the stromal microenvironment: direct contact, soluble factors, and extracellular vesicles","volume":"10","author":"Dubois N","year":"2020","unstructured":"Dubois N, Crompot E, Meuleman N,  Importance of crosstalk between chronic lymphocytic leukemia cells and the stromal microenvironment: direct contact, soluble factors, and extracellular vesicles. Front Oncol 2020;10:1422."},{"key":"B14","series-title":"Front Immunol","first-page":"965905","article-title":"Unravelling soluble immune checkpoints in chronic lymphocytic leukemia: physiological immunomodulators or immune dysfunction","volume":"13","author":"Landeira-Vi\u00f1uela A","year":"2022","unstructured":"Landeira-Vi\u00f1uela A, Arias-Hidalgo C, Juanes-Velasco P,  Unravelling soluble immune checkpoints in chronic lymphocytic leukemia: physiological immunomodulators or immune dysfunction. Front Immunol 2022;13:965905."},{"key":"B15","series-title":"Leukemia","first-page":"170","article-title":"Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function","volume":"27","author":"DiLillo DJ","year":"2013","unstructured":"DiLillo DJ, Weinberg JB, Yoshizaki A,  Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function. Leukemia 2013;27:170\u2013182."},{"key":"B16","series-title":"J Immunol","first-page":"4835","article-title":"CD5 promotes IL-10 production in chronic lymphocytic leukemia B cells through STAT3 and NFAT2 activation","volume":"186","author":"Garaud S","year":"2011","unstructured":"Garaud S, Morva A, Lemoine S,  CD5 promotes IL-10 production in chronic lymphocytic leukemia B cells through STAT3 and NFAT2 activation. J Immunol 2011;186:4835\u20134844."},{"key":"B17","series-title":"Blood","first-page":"3165","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu Y","year":"2021","unstructured":"Herishanu Y, Avivi I, Aharon A,  Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood 2021;137:3165\u20133173."},{"key":"B18","series-title":"Vaccine","first-page":"1122","article-title":"The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL)","volume":"39","author":"Whitaker JA","year":"2021","unstructured":"Whitaker JA, Parikh SA, Shanafelt TD,  The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL). Vaccine 2021;39:1122\u20131130."},{"key":"B19","series-title":"Eur J Immunol","first-page":"1403","article-title":"Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22","volume":"32","author":"Ghia P","year":"2002","unstructured":"Ghia P, Strola G, Granziero L,  Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22. Eur J Immunol 2002;32:1403\u20131413."},{"key":"B20","series-title":"Blood Adv","first-page":"4691","article-title":"Nurselike cells sequester B cells in disorganized lymph nodes in chronic lymphocytic leukemia via alternative production of CCL21","volume":"6","author":"Zaaboub R","year":"2022","unstructured":"Zaaboub R, Vimeux L, Contremoulins V,  Nurselike cells sequester B cells in disorganized lymph nodes in chronic lymphocytic leukemia via alternative production of CCL21. Blood Adv 2022;6:4691\u20134704."},{"key":"B21","series-title":"Haematologica","first-page":"562","article-title":"T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers","volume":"102","author":"Palma M","year":"2017","unstructured":"Palma M, Gentilcore G, Heimersson K,  T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers. Haematologica 2017;102:562\u2013572."},{"key":"B22","series-title":"Blood","first-page":"1412","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay AG","year":"2012","unstructured":"Ramsay AG, Clear AJ, Fatah R, Gribben JG. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood 2012;120:1412\u20131421."},{"key":"B23","series-title":"Leuk Res","first-page":"74","article-title":"Quantitative and qualitative analysis of regulatory T cells in B cell chronic lymphocytic leukemia","volume":"60","author":"Mpakou VE","year":"2017","unstructured":"Mpakou VE, Ioannidou HD, Konsta E,  Quantitative and qualitative analysis of regulatory T cells in B cell chronic lymphocytic leukemia. Leuk Res 2017;60:74\u201381."},{"key":"B24","series-title":"Leuk Lymphoma","first-page":"788","article-title":"Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia","volume":"50","author":"Jak M","year":"2009","unstructured":"Jak M, Mous R, Remmerswaal E,  Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:788\u2013801."},{"key":"B25","series-title":"Br J Haematol","first-page":"674","article-title":"Association of an increased frequency of CD14+HLA-DRlo\/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL)","volume":"156","author":"Gustafson MP","year":"2012","unstructured":"Gustafson MP, Abraham RS, Lin Y,  Association of an increased frequency of CD14+HLA-DRlo\/neg monocytes with decreased time to progression in chronic lymphocytic leukaemia (CLL). Br J Haematol 2012;156:674\u2013676."},{"key":"B26","series-title":"Sci Rep","first-page":"12572.","article-title":"BDNF belongs to the nurse-like cell secretome and supports survival of B chronic lymphocytic leukemia cells","volume":"10","author":"Talbot H","year":"2020","unstructured":"Talbot H, Saada S, Barthout E,  BDNF belongs to the nurse-like cell secretome and supports survival of B chronic lymphocytic leukemia cells. Sci Rep 2020;10:12572."},{"key":"B27","series-title":"Clin Immunol","first-page":"109601.","article-title":"Patterns of IgG testing and rates of hypogammaglobulinemia in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"250","author":"Sourmerai J","year":"2023","unstructured":"Sourmerai J, Yousif Z, Gift T,  Patterns of IgG testing and rates of hypogammaglobulinemia in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma. Clin Immunol 2023;250:109601."},{"key":"B28","series-title":"Blood Adv","first-page":"2188","article-title":"IgA levels at diagnosis predict for infections, time to treatment, and survival in chronic lymphocytic leukemia","volume":"3","author":"Ishdorj G","year":"2019","unstructured":"Ishdorj G, Streu E, Lambert P,  IgA levels at diagnosis predict for infections, time to treatment, and survival in chronic lymphocytic leukemia. Blood Adv 2019;3:2188\u20132198."},{"key":"B29","series-title":"Haematologica","first-page":"e300","article-title":"Incidence and predictors of infection among patients prior to treatment of chronic lymphocytic leukemia: a Danish nationwide cohort study","volume":"103","author":"Andersen MA","year":"2018","unstructured":"Andersen MA, Eriksen CT, Brieghel C,  Incidence and predictors of infection among patients prior to treatment of chronic lymphocytic leukemia: a Danish nationwide cohort study. Haematologica 2018;103:e300\u2013303."},{"key":"B30","series-title":"Blood","first-page":"2213","article-title":"Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"126","author":"Sun C","year":"2015","unstructured":"Sun C, Tian X, Lee YS,  Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood 2015;126:2213\u20132219."},{"key":"B31","series-title":"J Immunol","first-page":"3901","article-title":"Signaling through CD70 regulates B cell activation and IgG production","volume":"173","author":"Arens R","year":"2004","unstructured":"Arens R, Nolte MA, Tesselaar K,  Signaling through CD70 regulates B cell activation and IgG production. J Immunol 2004;173:3901\u20133908."},{"key":"B32","series-title":"Blood","first-page":"3168","article-title":"Chronic lymphocytic leukemia B cells inhibit spontaneous Ig production by autologous bone marrow cells: role of CD95-CD95L interaction","volume":"96","author":"Sampalo A","year":"2000","unstructured":"Sampalo A, Navas G, Medina F,  Chronic lymphocytic leukemia B cells inhibit spontaneous Ig production by autologous bone marrow cells: role of CD95-CD95L interaction. Blood 2000;96:3168\u20133174."},{"key":"B33","series-title":"Leukemia","first-page":"2563","article-title":"The association between deaths from infection and mutations of the BRAF, FBXW7, NRAS and XPO1 genes: a report from the LRF CLL4 trial","volume":"35","author":"Else M","year":"2021","unstructured":"Else M, Blakemore SJ, Strefford JC, Catovsky D. The association between deaths from infection and mutations of the BRAF, FBXW7, NRAS and XPO1 genes: a report from the LRF CLL4 trial. Leukemia 2021;35:2563\u20132569."},{"key":"B34","series-title":"Haematologica","first-page":"374","article-title":"Infections in chronic lymphocytic leukemia. Analysis of incidence as a function of length of follow-up","volume":"78","author":"Molica S","year":"1993","unstructured":"Molica S, Levato D, Levato L. Infections in chronic lymphocytic leukemia. Analysis of incidence as a function of length of follow-up. Haematologica 1993;78:374\u2013377."},{"key":"B35","series-title":"Blood","first-page":"3280","article-title":"Infection outcomes and hypogammaglobulinemia in patients with chronic lymphocytic leukemia treated with immunoglobulin replacement therapy","volume":"142","author":"Soumerai J","year":"2023","unstructured":"Soumerai J, Gift T, Yousif Z,  Infection outcomes and hypogammaglobulinemia in patients with chronic lymphocytic leukemia treated with immunoglobulin replacement therapy. Blood 2023;142:3280."},{"key":"B36","series-title":"Res Sq.","article-title":"CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancer","author":"Bange EM","unstructured":"Bange EM, Han NA, Wileyto P,  CD8 T cells compensate for impaired humoral immunity in COVID-19 patients with hematologic cancer. Res Sq. Preprint posted online February 2, 2021. doi: 10.21203\/rs.3.rs-162289\/v1"},{"key":"B37","series-title":"Blood","first-page":"1612","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches JC","year":"2013","unstructured":"Riches JC, Davies JK, McClanahan F,  T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood 2013;121:1612\u20131621."},{"key":"B38","series-title":"Blood Adv","first-page":"5294","article-title":"Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study","volume":"7","author":"Moreno C","year":"2023","unstructured":"Moreno C, Solman IG, Tam CS,  Immune restoration with ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia: the phase 2 CAPTIVATE study. Blood Adv 2023;7:5294\u20135303."},{"key":"B39","series-title":"Blood Adv","first-page":"4849","article-title":"Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy","volume":"4","author":"Davis JE","year":"2020","unstructured":"Davis JE, Handunnetti SM, Ludford-Menting M,  Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy. Blood Adv 2020;4:4849\u20134859."},{"key":"B40","series-title":"JAMA","first-page":"267","article-title":"Subsequent neoplasia in chronic lymphocytic leukemia","volume":"232","author":"Manusow D","year":"1975","unstructured":"Manusow D, Weinerman BH. Subsequent neoplasia in chronic lymphocytic leukemia. JAMA 1975;232:267\u2013269."},{"key":"B41","series-title":"Leukemia","first-page":"3197","article-title":"Second cancer incidence in CLL patients receiving BTK inhibitors","volume":"34","author":"Bond DA","year":"2020","unstructured":"Bond DA, Huang Y, Fisher JL,  Second cancer incidence in CLL patients receiving BTK inhibitors. Leukemia 2020;34:3197\u20133205."},{"key":"B42","series-title":"J Clin Oncol","first-page":"904","article-title":"Other malignancies in chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"27","author":"Tsimberidou AM","year":"2009","unstructured":"Tsimberidou AM, Wen S, McLaughlin P,  Other malignancies in chronic lymphocytic leukemia\/small lymphocytic lymphoma. J Clin Oncol 2009;27:904\u2013910."},{"key":"B43","series-title":"Blood Cancer J","first-page":"75.","article-title":"Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia","volume":"9","author":"Kumar V","year":"2019","unstructured":"Kumar V, Ailawadhi S, Bojanini L,  Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia. Blood Cancer J 2019;9:75."},{"key":"B44","series-title":"Leukemia","first-page":"331","article-title":"Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis","volume":"30","author":"Solomon BM","year":"2016","unstructured":"Solomon BM, Chaffee KG, Moreira J,  Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis. Leukemia 2016;30:331\u2013336."},{"key":"B45","series-title":"EJHaem","first-page":"129","article-title":"Second primary malignancies in chronic lymphocytic leukaemia: skin, solid organ, haematological and Richter\u2019s syndrome","volume":"3","author":"Shen Y","year":"2022","unstructured":"Shen Y, Coyle L, Kerridge I,  Second primary malignancies in chronic lymphocytic leukaemia: skin, solid organ, haematological and Richter\u2019s syndrome. EJHaem 2022;3:129\u2013138."},{"key":"B46","series-title":"Nat Commun","first-page":"2147.","article-title":"Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia","volume":"14","author":"Al-Sawaf O","year":"2023","unstructured":"Al-Sawaf O, Zhang C, Jin HY,  Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. Nat Commun 2023;14:2147."},{"key":"B47","series-title":"Blood","first-page":"2031","article-title":"Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab","volume":"133","author":"Byrd JC","year":"2019","unstructured":"Byrd JC, Hillmen P, O\u2019Brien S,  Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood 2019;133:2031\u20132042."},{"key":"B48","series-title":"J Clin Oncol","first-page":"930","article-title":"Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study","volume":"31","author":"Solomon BM","year":"2013","unstructured":"Solomon BM, Rabe KG, Slager SL,  Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study. J Clin Oncol 2013;31:930\u2013937."},{"key":"B49","series-title":"Semin Oncol","first-page":"230","article-title":"Autoimmune complications of chronic lymphocytic leukemia","volume":"33","author":"Hamblin TJ","year":"2006","unstructured":"Hamblin TJ. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol 2006;33:230\u2013239."},{"key":"B50","series-title":"Sci Rep","first-page":"16357","article-title":"Chronic lymphocytic leukemia-associated paraneoplastic pemphigus: potential cause and therapeutic strategies","volume":"10","author":"Cao L","year":"2020","unstructured":"Cao L, Wang F, Du XY,  Chronic lymphocytic leukemia-associated paraneoplastic pemphigus: potential cause and therapeutic strategies. Sci Rep 2020;10:16357."},{"key":"B51","series-title":"Haematologica","first-page":"1180","article-title":"Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience","volume":"100","author":"Strati P","year":"2015","unstructured":"Strati P, Nasr SH, Leung N,  Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience. Haematologica 2015;100:1180\u20131188."},{"key":"B52","series-title":"Blood","first-page":"2007","article-title":"Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells","volume":"105","author":"Hall AM","year":"2005","unstructured":"Hall AM, Vickers MA, McLeod E, Barker RN. Rh autoantigen presentation to helper T cells in chronic lymphocytic leukemia by malignant B cells. Blood 2005;105:2007\u20132015."},{"key":"B53","series-title":"Br J Haematol","first-page":"800","article-title":"Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab\u2013incidence and predictors","volume":"136","author":"Borthakur G","year":"2007","unstructured":"Borthakur G, O\u2019Brien S, Wierda WG,  Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab\u2013incidence and predictors. Br J Haematol 2007;136:800\u2013805."},{"key":"B54","series-title":"Leuk Lymphoma","first-page":"42","article-title":"Vaccination efficacy in patients with chronic lymphocytic leukemia","volume":"64","author":"Wang KY","year":"2023","unstructured":"Wang KY, Shah P, Skavla B,  Vaccination efficacy in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2023;64:42\u201356."},{"key":"B55","series-title":"Leukemia","first-page":"737","article-title":"Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL)","volume":"35","author":"Mauro FR","year":"2021","unstructured":"Mauro FR, Giannarelli D, Galluzzo CM,  Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL). Leukemia 2021;35:737\u2013746."},{"key":"B56","series-title":"Blood Adv","first-page":"2624","article-title":"Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients","volume":"5","author":"Vijenthira A","year":"2021","unstructured":"Vijenthira A, Gong I, Betschel SD,  Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients. Blood Adv 2021;5:2624\u20132643."},{"key":"B57","series-title":"Br J Haematol","first-page":"712","article-title":"Lack of adequate pneumococcal vaccination response in chronic lymphocytic leukaemia patients receiving ibrutinib","volume":"182","author":"Andrick B","year":"2018","unstructured":"Andrick B, Alwhaibi A, DeRemer DL,  Lack of adequate pneumococcal vaccination response in chronic lymphocytic leukaemia patients receiving ibrutinib. Br J Haematol 2018;182:712\u2013714."},{"key":"B58","series-title":"Blood Adv","first-page":"4728","article-title":"Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia","volume":"7","author":"Ujjani C","year":"2023","unstructured":"Ujjani C, Gooley TA, Spurgeon SE,  Diminished humoral and cellular responses to SARS-CoV-2 vaccines in patients with chronic lymphocytic leukemia. Blood Adv 2023;7:4728\u20134737."},{"key":"B59","series-title":"PLoS Med","first-page":"e1004157.","article-title":"Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: a prospective cohort study","volume":"20","author":"Qin K","year":"2023","unstructured":"Qin K, Honjo K, Sherrill-Mix S,  Exposure of progressive immune dysfunction by SARS-CoV-2 mRNA vaccination in patients with chronic lymphocytic leukemia: a prospective cohort study. PLoS Med 2023;20:e1004157."},{"key":"B60","article-title":"NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections. Version 3.2024","author":"Baden LR","unstructured":"Baden LR, Swaminathan S, Almyroudis NG,  NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections. Version 3.2024. To view the most recent version, visit https:\/\/www.nccn.org\/"},{"key":"B61","article-title":"NCCN Clinical Practice Guidelines in Oncology: Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma. Version 1.2025","author":"Wierda WG","unstructured":"Wierda WG, Brown J, Abramson JS,  NCCN Clinical Practice Guidelines in Oncology: Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma. Version 1.2025. To view the most recent version, visit https:\/\/www.nccn.org\/"},{"key":"B62","series-title":"N Engl J Med","first-page":"902","article-title":"Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia","volume":"319","author":"Gale RP","year":"1988","unstructured":"Gale RP, Chapel HM, Bunch C,  Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. N Engl J Med 1988;319:902\u2013907."},{"key":"B63","series-title":"PLoS One","first-page":"e0258529.","article-title":"Subcutaneous immunoglobulin replacement for treatment of humoral immune dysfunction in patients with chronic lymphocytic leukemia","volume":"16","author":"Mustafa SS","year":"2021","unstructured":"Mustafa SS, Jamshed S, Vadamalai K, Ramsey A. Subcutaneous immunoglobulin replacement for treatment of humoral immune dysfunction in patients with chronic lymphocytic leukemia. PLoS One 2021;16:e0258529."},{"key":"B64","series-title":"Lancet","first-page":"1278","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman JP","year":"2020","unstructured":"Sharman JP, Egyed M, Jurczak W,  Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet 2020;395:1278\u20131291."},{"key":"B65","series-title":"Lancet Oncol","first-page":"1031","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam CS","year":"2022","unstructured":"Tam CS, Brown JR, Kahl BS,  Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol 2022;23:1031\u20131043."},{"key":"B66","series-title":"Lancet Oncol","first-page":"1188","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf O","year":"2020","unstructured":"Al-Sawaf O, Zhang C, Tandon M,  Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2020;21:1188\u20131200."},{"key":"B67","series-title":"Hematology Am Soc Hematol Educ Program","first-page":"450","article-title":"Disease-specific complications of chronic lymphocytic leukemia","volume":"2008","author":"Dearden C","year":"2008","unstructured":"Dearden C. Disease-specific complications of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2008;2008:450\u2013456."},{"key":"B68","series-title":"Int J Mol Sci","first-page":"1825","article-title":"Immune response dysfunction in chronic lymphocytic leukemia: dissecting molecular mechanisms and microenvironmental conditions","volume":"21","author":"Arruga F","year":"2020","unstructured":"Arruga F, Gyau BB, Iannello A,  Immune response dysfunction in chronic lymphocytic leukemia: dissecting molecular mechanisms and microenvironmental conditions. Int J Mol Sci 2020;21:1825."},{"key":"B69","series-title":"J Immunol","first-page":"719","article-title":"Chronic lymphocytic leukemia: a paradigm of innate immune cross-tolerance","volume":"194","author":"Jurado-Camino T","year":"2015","unstructured":"Jurado-Camino T, Cordoba R, Esteban-Burgos L,  Chronic lymphocytic leukemia: a paradigm of innate immune cross-tolerance. J Immunol 2015;194:719\u2013727."},{"key":"B70","series-title":"Oncotarget","first-page":"84889","article-title":"Neutrophils in chronic lymphocytic leukemia are permanently activated and have functional defects","volume":"8","author":"Manukyan G","year":"2017","unstructured":"Manukyan G, Papajik T, Gajdos P,  Neutrophils in chronic lymphocytic leukemia are permanently activated and have functional defects. Oncotarget 2017;8:84889\u201384901."},{"key":"B71","series-title":"Oncotarget","first-page":"46301","article-title":"Deregulation of SOCS5 suppresses dendritic cell function in chronic lymphocytic leukemia","volume":"7","author":"Toniolo PA","year":"2016","unstructured":"Toniolo PA, Liu S, Yeh JE,  Deregulation of SOCS5 suppresses dendritic cell function in chronic lymphocytic leukemia. Oncotarget 2016;7:46301\u201346314."},{"key":"B72","series-title":"Oncoimmunology","first-page":"e1330235.","article-title":"NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors","volume":"6","author":"MacFarlane IA","year":"2017","unstructured":"MacFarlane IA, Jillab M, Smith MR,  NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors. Oncoimmunology 2017;6:e1330235."},{"key":"B73","series-title":"Leukemia","first-page":"3634","article-title":"T-cells in chronic lymphocytic leukemia: guardians or drivers of disease?","volume":"35","author":"Roessner PM","year":"2021","unstructured":"Roessner PM, Seiffert M. T-cells in chronic lymphocytic leukemia: guardians or drivers of disease? Leukemia 2021;35:3634\u20132024."},{"key":"B74","series-title":"Blood","first-page":"2283","article-title":"Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions","volume":"131","author":"Puente XS","year":"2018","unstructured":"Puente XS, Jares P, Campo E. Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions. Blood 2018;131:2283\u20132296."},{"key":"B75","series-title":"J Clin Invest","first-page":"3052","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long M","year":"2017","unstructured":"Long M, Beckwith K, Do P,  Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest 2017;127:3052\u20133064."},{"key":"B76","series-title":"Hematol Oncol","first-page":"392","article-title":"The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"37","author":"Zou YX","year":"2019","unstructured":"Zou YX, Zhu HY, Li XT,  The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma. Hematol Oncol 2019;37:392\u2013400."},{"key":"B77","series-title":"Clin Cancer Res","first-page":"1572","article-title":"Disruption of in vivo chronic lymphocytic leukemia tumor\u2013microenvironment interactions by ibrutinib\u2013findings from an investigator-initiated phase II study","volume":"22","author":"Niemann CU","year":"2016","unstructured":"Niemann CU, Herman SE, Maric I,  Disruption of in vivo chronic lymphocytic leukemia tumor\u2013microenvironment interactions by ibrutinib\u2013findings from an investigator-initiated phase II study. Clin Cancer Res 2016;22:1572\u20131582."},{"key":"B78","series-title":"Blood Adv","first-page":"2642","article-title":"Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment","volume":"3","author":"de Weerdt I","year":"2019","unstructured":"de Weerdt I, Hofland T, de Boer R,  Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment. Blood Adv 2019;3:2642\u20132652."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/3\/article-e247090.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/3\/article-e247090.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/3\/article-e247090.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T09:13:27Z","timestamp":1741770807000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/3\/article-e247090.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":78,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2024.7090","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]}}}